FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCountdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
Brexit & the future landscape for clinical trial supplies in the UK and Europe
Topics: Pharma Industry, Regulatory, Supply Chain
Position Paper
Free
2020 Virtual Conference: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members